首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 203 毫秒
1.
目的:探讨干扰素(IFN)-α/β受体启动子-408位点的单核苷酸多态性(SNP)与IFN疗效的关系。方法:应用聚合酶链反应(PCR)并基因测序法检测210例慢性乙型肝炎(CHB)患者(轻度38例、中度102例、重度70例)的IFN-α/β受体基因启动子-408位点的SNP。对210例中既往未用过IFN治疗的80例CHB患者给予聚乙二醇化干扰素α-2a or 2b(Peg-IFN-α-2a/2b)治疗48周。比较SNP与Peg-IFN疗效的关系。结果:80例患者中,IFN治疗持久应答(SR)33例(41.3%),非持久应答(NSR)47例(58.7%)。IFN-α/β受体启动子-408位点CT基因型患者干扰素治疗SR为65%(13/20),显著高于CC基因型患者干扰素治疗SR 29.5%(13/44),两者比较差异有显著性意义(χ2=7.166,P=0.007)。干扰素治疗SR组IFN-α/β-408位点等位基因C、T的频率与NSR组的频率比较差异无显著性意义(P>0.05)。结论:IFN-α/β受体启动子-408为CT杂合基因型的CHB患者可能对Pec-IFN治疗效果较好。  相似文献   

2.
目的:探讨分析TLR10基因多态性与HBeAg阳性慢性乙型肝炎(CHB)患者聚乙二醇化干扰素α(PEG-IFNα)治疗临床归转的相关性。方法:选取2019年8月至2020年8月收治的92例HBeAg阳性CHB患者,均予以PEG-IFNα进行治疗,6个月后根据HBeAg、HBeAb情况将患者分为应答组44例和非应答组48例。提取全血基因组DNA,测定TLR10基因多态性点位(RS10004195位点和RS11096957位点),分析其不同点位基因型和等位基因分布与乙型肝炎病毒感染的关系,进而探讨TLR10基因多态性与临床转归的相关性。结果:TLR10基因RS10004195位点基因型中,应答组AA+AT型基因分布频率为77.27%显著高于非应答组的52.08%,A等位基因频率65.91%显著高于非应答组的41.67%,差异有统计学意义(P<0.05);TLR10基因RS11096957位点基因型中,应答组AC+AA型基因分布频率为70.45%,与非应答组的62.50%差异无统计学意义(P>0.05),应答组A等位基因频率为61.36%显著高于非应答组的39.58%,差异有统计...  相似文献   

3.
目的 探讨慢性乙型肝炎(CHB)患者血清降钙素基因相关肽(CGRP)和α-干扰素-λ4(IFNL4)基因多态性对α-干扰素治疗应答的影响。方法 2018年9月~2021年2月我院诊治的CHB患者92例,给予所有患者α-干扰素α-2b治疗1年。采用聚合酶链反应-限制性片段长度多态性检测血CGRP基因rs155209位点及IFNL4基因rs368234815和rs12979860位点多态性,应用Logistic回归分析基因多态性与α-干扰素治疗应答的关系。结果 在治疗1年末,本组应答67例(72.8%),未获得完全应答25例(27.2%);非应答组CGRP-rs155209位点CC基因型和等位基因C比率分别为36.0%和56.0%,显著高于应答组的16.4%和32.8%(P<0.05);非应答组IFNL4-rs368234815位点TT/TT基因型和TT基因频率分别为76.0%和86.0%,显著低于应答组的92.5%和95.5%(P<0.05);非应答组IFNL4-rs12979860位点CC、CT和TT基因型比率分别为44.0%、44.0%和12.0%,与应答组的40.3%、46.3%和13.4%比,无显著性差异(P>0.05);应用非条件Logistic回归模型计算校正性别和年龄,结果显示CGRP-rs155209位点CC基因型是影响治疗无应答的危险基因型【OR值为1.489(95%CI:1.103~2.009)】,而IFNL4-rs368234815位点TT/TT 基因型是α-干扰素治疗应答的保护基因型【OR值为0.652(95%CI:0.477~0.893)】。结论 CGRP基因rs155209位点CC基因型是接受α-干扰素治疗CHB患者可能无应答的危险基因型,而IFNL4基因rs368234815 位点TT/TT 基因型可能是治疗应答的保护基因型,将影响CHB患者对α-干扰素治疗的生化和病毒学应答反应。  相似文献   

4.
目的探讨雌激素受体α基因PvuⅡ多态性与慢性乙型肝炎患者干扰素治疗发生早期应答的相关性。方法采用聚合酶链反应-限制性片段长度多态性法检测100例首次接受干扰素治疗的慢性乙型肝炎患者外周血雌激素α受体基因PvuⅡ多态性,并分析了基因型与干扰素早期应答的相关性。结果在雌激素受体基因PvuⅡ的PP、Pp和pp三个基因型间,PP基因型患者早期病毒学应答率(70.8%)明显高于Pp(40.0%)和pp(37.2%)基因型,差异具有统计学意义(P0.05),但早期联合应答率和早期HBeAg血清转换率在PP、Pp和pp三种基因型间的差异均无统计学意义(P0.05)。结论研究提示PvuⅡ多态性检测可能是预测慢性乙型肝炎患者干扰素-α治疗后早期应答率的重要因素之一。  相似文献   

5.
目的:研究白细胞介素-10(IL-10)基因启动子区域-1082、-592位点单核苷酸多态性(SNP)与乙肝病毒感染后临床转归之间的关系。方法:采用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)方法分析175例乙型肝炎患者和153例正常对照者IL-10基因启动子区域-592、-1082位点的基因多态性,并结合临床资料进行统计学分析。结果:IL-10-592位点在患者组和正常对照组均发现AA、AC、CC 3种基因型,各基因型在患者组和对照组分布上差异均无显著性意义。而IL-10-1082位点在正常对照组有AA、AG、GG 3种基因型,而患者组只发现AA、AG两种基因型。经统计学分析,在基因型分布上,慢性乙型肝炎组与急性乙型肝炎组、重型肝炎组比较差异均有显著性意义(P0.001,P0.05);而与肝硬化组相比差异无显著性意义。另外,肝硬化组与急性乙型肝炎组基因型分布的差异亦有显著性意义(P=0.020)。结论:IL-10-1082A等位基因及AA基因型与乙肝病毒感染及感染后转归相关。  相似文献   

6.
目的 探讨慢性乙型肝炎患者的Ⅰ型干扰素受体1(IFNAR1)基因启动子多态性和IFN-α治疗应答之间的关系.方法 选择接受IFN-α治疗的慢性乙型肝炎患者61例,采用重组IFN-α2b 500万U,隔天肌内注射,疗程48周,观察应答情况,对入选患者的IFNAR1基因启动子区进行测序,计量资料采用t检验,计数资料采用卡方检验.结果 治疗的慢性乙型肝炎患者中,完全应答22例,部分应答8例,无应答31例.IFNAR1基因启动子区一408C/T、-3C/T、-77GT双核苷酸重复序列[-77(GT),]存在基因多态性,这三个位点基因多态性存在连锁,形成-408C/-77(GT)5/-3C等基因单体型.IFNAR1启动子区基因型为-408C/-77(GT)5/-3C及-408C/-77(GT)5/-3C的,基因型为-408C/-77(GT)5/-3C和非-408C/-77(GT)5/-3C的慢性乙型肝炎患者对IFN-α的应答率为61.0%,高于基因型为非-408C/-77(GT)5/-3C,非-408C/-77(GT)5/-3C患者的25.0%(X2=6.961,P=0.008).结论 IFNAR1启动子基因型为-408C/-77(GT)5/-3C及-408C/-77(GT)5/-3C的,-408C/-77(GT)5/-3C和非-408C/-77(GT)5/-3C的慢性乙型肝炎患者对IFN-α治疗应答较好,IFNAR1基因启动子多态性与慢性乙型肝炎患者的干扰素应答有关.  相似文献   

7.
HBV基因型与干扰素抗病毒疗效的关系   总被引:7,自引:1,他引:7  
目的:探讨HBV不同基因型对α-干扰素抗病毒疗效的影响.方法:选取应用α-干扰素进行抗病毒治疗的慢性乙型肝炎患者作为研究对象,观察其抗病毒疗效.患者的HBV基因型采用PCR微板核酸杂交-ELISA方法检测;血清HBV DNA复制水平采用荧光定量PCR检测;HBV前C区和BCP(基础核心启动子)区基因位点变异采用HBV基因多态性芯片进行检测.结果:94例慢性乙型肝炎患者的HBV基因型以C型、B型为主,未发现A、E、F基因型.HBV DNA高复制水平明显与C基因型及混合基因型有关.B基因型对α-干扰素抗病毒治疗的应答明显优于C、D型,而混合基因型对α-干扰素的应答最不敏感.仅B基因型对α-干扰素治疗产生完全应答.部分应答及无应答时HBeAg的转阴与HBV前C区nt 1 896位点变异、以及BCP区nt 1 762、nt 1 764双位点变异有关.C基因型HBV前C区及BCP区基因变异发生率明显高于B型.结论:HBV基因型与HBV DNA复制水平、HBV基因变异以及α-干扰素抗病毒疗效均有一定的相关性,提示HBV基因分型有重要的临床意义.  相似文献   

8.
目的探讨IL28B基因多态性与HBeAg阳性慢性乙型肝炎患者聚乙二醇化干扰素α(PEG-IFN)治疗应答的关系。方法采集212例接受PEG-IFN治疗48周的HBeAg阳性慢性乙型肝炎患者外周血,提取基因组DNA,应用时间飞行质谱技术(MassARRAY)检测IL28B基因的3个SNP位点rs12980275、rs12979860、rs8099917的多态性。应答定义为:PEG-IFN治疗48周,患者HBV DNA<200 IU/mL、HBeAg血清学转换及ALT复常。结果应答患者为74例,无应答者138例,应答率为34.9%。HBV基因分型以C型为主(C型117例,B型95例)。rs12980275基因型AA和N-AA(AG/GG)的比例分别为77.8%和22.2%;rs12979860基因型CC和N-CC(CT/TT)的比例分别为78.3%和21.7%;rs8099917基因型TT和N-TT(TG/GG)的比例分别为79.2%和20.8%。这3个SNP位点干扰素治疗应答组和非应答组中等位基因的频率和基因型的分布差异均有统计学意义(P<0.05)。在多因素分析中,校正了性别、年龄、HBV基因型、基线HBV DNA水平及基线ALT水平后,发现IL28B野生纯合基因型(AA、CC和TT型)是PEGIFN高应答率的独立预测因素。其中rs12980275基因型AA、N-AA的有效率分别为38.8%、21.3%(OR 2.70,95%CI1.21~6.01;P=0.015);rs12979860基因型CC、N-CC的有效率分别为38.6%、21.7%(OR 2.56,95%CI 1.15~5.67;P=0.021);rs8099917基因型TT、N-TT的有效率分别为38.7%、20.5%(OR 2.80,95%CI 1.23~6.39;P=0.015)。此外,还发现了一个由rs12980275和rs12979860组成的单体域,其中单体型A-C与干扰素高应答率显著相关(OR2.53,95%CI 1.20~5.34;P=0.015)。结论IL28B基因多态性与HBeAg阳性慢性乙型肝炎患者对PEG-IFN治疗的应答密切相关,IL28B野生纯合基因型(AA、CC和TT型)是PEG-IFN高应答率的独立预测因素。  相似文献   

9.
乙型肝炎病毒基因型与干扰素α1b疗效关系的研究   总被引:5,自引:0,他引:5  
目的 探讨乙型肝炎病毒 (HBV)基因型与干扰素α1b治疗慢性乙型肝炎疗效的关系。方法 采用PCR、核酸杂交和酶联显色技术对慢性乙型肝炎患者进行HBV基因分型 ,随机观察 10 5例 (B型 5 3例和C型 5 2例 )慢性乙型肝炎患者干扰素α1b治疗 6个月和随访半年后肝功能和病毒学指标的变化。结果 干扰素α1b治疗 6个月和随访半年后 ,B基因型患者的HBeAg阴转率、HBVDNA阴转率和HBeAg/抗 HBe的血清转换率均显著高于C基因型 (P <0 . 0 1) ,B基因型患者的有效应答率为 5 2 . 83 %,显著高于C基因型的 2 5 . 0 0 %(P <0 . 0 1)。B基因型的持续应答率高于C型 ,复发率低于C型 ,但两组差异无显著性 (P >0 . 0 5 )。结论 B基因型对干扰素α1b的抗病毒疗效显著高于C型 ,HBV基因型是影响干扰素α1b疗效的重要因素之一。  相似文献   

10.
目的探讨干扰素-γ(IFN-γ)启动子基因874位点的单核苷酸多态性(SNP)与IFNα-2b治疗慢性乙肝(CHB)持久应答的关系。方法选择CHB患者106例,应用PCR-SSP技术分析宿主的IFN-γ启动子基因874位点的SNP,患者给予IFNα-2b治疗1年,随访1年,比较SNP与IFNα-2b疗程结束时完全应答、停药后随访1年完全应答(持久应答)的关系。结果在标准疗程结束时,完全应答的患者中三种基因型的分布无统计学差异(χ2=3.594 9,P=0.165 7)。而在持久应答患者中三种基因型的分布有统计学差异,TT基因型患者的持久应答率高于其他两种基因型患者(χ2=6.639 8,P=0.036 1)。结论 CHB患者对IFNα-2b治疗的持久应答与IFN-γ基因型有一定关联性,尤其与TT基因型关联更大。  相似文献   

11.
OBJECTIVE: To assess the roles of the interleukin 4 (IL-4) and interferon-g (IFN-g) gene polymorphisms in a series of patients with biopsy-proven giant cell arteritis (GCA). METHODS: Eighty-two patients with biopsy-proven GCA and 102 ethnically matched controls from the Lugo region (Northwest Spain) were studied. The following single nucleotide polymorphisms (SNP) were assessed: IL-4 (SNP1: rs2070874, SNP2: rs2227284, SNP3: rs2227282, SNP4: rs2243266, and SNP5: rs2243267) and IFN-g (SNP1: rs1861494, SNP2: rs1861493, and SNP3: rs2069718). RESULTS: Significant differences in allele and genotype frequencies were observed for the IL-4 SNP between HLA-DRB1*04 negative patients and controls. Epistatic interaction between SNP2 (rs2227284) with HLA-DRB1 showed a significant interaction (p = 0.001) and carriage of the SNP2*T allele in the absence of HLA-DRB1*04 resulted in a 4-fold risk of developing GCA (OR 4.2, 95% CI 1.1-15.6). Also, a significant increase in the frequency of the T-T-C-A-C IL-4 haplotype was observed in HLA-DRB1*04 negative GCA patients compared to the controls (p = 0.02; OR 2.0, 95% CI 1.0-3.9). Similar distributions of allele and genotype frequencies were observed for the IFN-g polymorphisms in both GCA patients and controls. CONCLUSION: Our results suggest an association with IL-4 gene polymorphism that is dependent on HLA-DRB1 genotype in GCA susceptible individuals. These data indicate an interaction between HLA-DRB1 and IL-4 that contributes to pronounced disease susceptibility.  相似文献   

12.
AIM: To study the relationship of human leukocyte antigen (HLA)-DRB1 and -DQB1 alleles with the genetic susceptibility to HBV infection and the response to interferon (IFN) in HBV-infected patients.METHODS: Low-resolution DNA typing kit was used to determine HLA-DR-1 and -DQB1 genes in 72 patients with chronic hepatitis B (CHB) and HLA-DRB1 in 200 healthy people ready to donate their bone marrow in Shanghai.Among CHB patients, 35 were treated with IFNα-1b for 24 wk.RESULTS: The frequencies of HLA-DRB1*06, DRB1*08and DRB1*16 alleles in 72 patients were higher than in 200 healthy people (2.08% vs0%, OR = 3.837, P= 0.018;11.11% vs5.50%, OR = 2.148, P= 0.034; and 6.94% vs 3.00%, OR = 0.625, P = 0.049, respectively); whereas that of DRB1*07 allele was lower (2.78% vs 7.75%,OR = 0.340, P = 0.046). The frequency of HLA-DRB1* 14allele was higher in 11 responders to IFN compared with 24 non-responders (18.18% vs2.08%, OR = 10.444,P = 0.031), whereas that of DQB1*07 allele was inverse (9.09% vs 37.50%, OR = 0.167, P= 0.021).CONCLUSION: The polymorphism of HLA class Ⅱ may influence the susceptibility to HBV infection and the response to IFN in studied CHB patients. Compared with other HLA-DRB1 alleles, HLA-DRB1*06, DRB1*08, and DRB1*16 may be associated with chronicity of HBV infection, HLA-DRB1*07 with protection against HBV infection, and HLA-DRB1*14 allele may be associated with a high rate of the response of CHB patients to IFN treatment.Compared with other HLA-DQB1 alleles, HLA-DQB1*07 may be associated with low response rate to IFN.  相似文献   

13.
OBJECTIVE: To analyze whether the polymorphisms -22 (G/C) and -348 (C/T) of the BAT1 gene are associated with susceptibility to rheumatoid arthritis (RA). METHODS: One hundred fifty-six patients with RA and 154 controls were genotyped for HLA-DRB1 and the polymorphisms -22 and -348 of the BAT1 gene. RESULTS: HLA-DRB1*04 alleles were associated with RA susceptibility (33.9% vs 20.1%; pc = 0.04). Among these, HLA-DRB1*0401 (13.4% vs 5.1%; pc = 0.04) and HLA-DRB1*0404 (5.7% vs 1.2%; pc = 0.2) were increased in patients with RA. Additionally, carriage of BAT1 -348T polymorphism was strongly associated with RA (23.7% vs 12.1%; pc = 0.0002). Significantly, BAT1 -348T was in linkage disequilibrium with HLA-DRB1*0404 and HLA-DRB1*0405. However, BAT1 -348 T was associated independently with HLA-DRB1 shared-epitope alleles (42.6% vs 18.9%; p = 0.001). CONCLUSION: The BAT1 -348T polymorphism is associated with RA susceptibility independently of HLA-DRB1. The role of BAT1 in the regulation of tumor necrosis factor-a suggests that BAT1 may regulate the inflammatory response observed in patients with RA.  相似文献   

14.
AIM: To study the relationship of human leukocyte antigen (HLA)-DRB1 and -DQB1 alleles with the genetic susceptibility to HBV infection and the response to interferon (IFN) in HBV-infected patients. METHODS: Low-resolution DNA typing kit was used to determine HLA-DR-1 and -DQB1 genes in 72 patients with chronic hepatitis B (CHB) and HLA-DRB1 in 200 healthy people ready to donate their bone marrow in Shanghai. Among CHB patients, 35 were treated with IFNa-lb for 24 wk. RESULTS: The frequencies of HLA-DRB1~*06, DRB1~*08 and DRB1~*16 alleles in 72 patients were higher than in 200 healthy people (2.08% vs0%, OR=3.837, P=0.018; 11.11% vs 5.50%, OR=2.148, P=0.034; and 6.94% vs 3.00%, OR=0.625, P=0.049, respectively); whereas that of DRB1~*07 allele was lower (2.78% vs 7.75%, OR=0.340, P=0.046). The frequency of HLA-DRB1~*14 allele was higher in 11 responders to IFN compared with 24 non-responders (18.18% vs 2.08%, OR=10.444, P=0.031), whereas that of DQB1*07 allele was inverse (9.09% vs 37.50%, OR=0.167, P=0.021). CONCLUSION: The polymorphism of HLA class II may influence the susceptibility to HBV infection and the response to IFN in studied CHB patients. Compared with other HLA-DRB1 alleles, HLA-DRB1~*06, DRB1~*08, and DRB1~*16 may be associated with chronicity of HBV infection, HLA-DRB1~*07 with protection against HBV infection, and HLA-DRB1~*14 allele may be associated with a high rate of the response of CHB patients to IFN treatment. Compared with other HLA-DQB1 alleles, HLA-DQB1~*07 may be associated with low response rate to IFN.  相似文献   

15.
目的研究新疆维吾尔族慢性胃炎患者HLA-DRB1等位基因与幽门螺杆菌(Hp)感染的关系。方法采用幽门螺杆菌分离培养技术检测33例维吾尔族慢性胃炎患者幽门螺杆菌感染情况,采用PCR-SSP检测HLA-DRB1*0405、HLA-DRB1*08、HLA-DRB1*12等位基因,并与36例汉族慢性胃炎患者进行比较。结果1)新疆维吾尔族慢性胃炎患者Hp阳性率(78.8%)显著高于汉族慢性胃炎患者(58.3%)(P〈0.05);2)维吾尔族、汉族慢性胃炎患者Hp感染与HLA-DRB1*0405、HLA-DRB1*08、HLA-DRB1*12等位基因无相关性(P〉0.05)。结论1)维吾尔族慢性胃炎患者Hp感染率高于汉族慢性胃炎患者;2)维吾尔族、汉族慢性胃炎患者Hp感染与HLA-DRB1*0405、HLA-DRB1*08、HLA-DRB1*12等位基因无关。  相似文献   

16.
OBJECTIVE: We have previously identified a single-nucleotide polymorphism (SNP) haplotype involving the lymphotoxin alpha (LTA) and tumor necrosis factor (TNF) loci (termed haplotype LTA-TNF2) on chromosome 6 that shows differential association with rheumatoid arthritis (RA) on HLA-DRB1*0404 and *0401 haplotypes, suggesting the presence of additional non-HLA-DRB1 RA susceptibility genes on these haplotypes. To refine this association, we performed a case-control association study using both SNPs and microsatellite markers in haplotypes matched either for HLA-DRB1*0404 or for HLA-DRB1*0401. METHODS: Fourteen SNPs lying between HLA-DRB1 and LTA were genotyped in 87 DRB1*04-positive families. High-density microsatellite typing was performed using 24 markers spanning 2,500 kb centered around the TNF gene in 305 DRB1*0401 or *0404 cases and 400 DRB1*0401 or *0404 controls. Single-marker, 2-marker, and 3-marker minihaplotypes were constructed and their frequencies compared between the DRB1*0401 and DRB1*0404 matched case and control haplotypes. RESULTS: Marked preservation of major histocompatibility complex haplotypes was seen, with chromosomes carrying LTA-TNF2 and either DRB1*0401 or DRB1*0404 both carrying an identical SNP haplotype across the 1-Mb region between TNF and HLA-DRB1. Using microsatellite markers, we observed two 3-marker minihaplotypes that were significantly overrepresented in the DRB1*0404 case haplotypes (P = 0.00024 and P = 0.00097). CONCLUSION: The presence of a single extended SNP haplotype between LTA-TNF2 and both DRB1*0401 and DRB1*0404 is evidence against this region harboring the genetic effects in linkage disequilibrium with LTA-TNF2. Two RA-associated haplotypes on the background of DRB1*0404 were identified in a 126-kb region surrounding and centromeric to the TNF locus.  相似文献   

17.
中国人群HLA-DRB1基因多态性与慢性乙型肝炎关系的Meta分析   总被引:2,自引:0,他引:2  
目的:用Meta分析的方法综合评价中国人群HLA-DRB1基因多态性与慢性乙型肝炎的关系.方法:检索中国生物医学文献数据库、维普数据库和Medline数据库,依据选择标准收集所有相关的病例对照研究,应用RevMan4.2软件对符合条件的研究结果进行Meta分析.结果:符合纳入标准的共8篇文献,包含慢性乙型肝炎组501例和正常对照组855例.经综合分析:HLA-DRB1*03和HLA-DRB1*08可能为中国人群慢性乙型肝炎的易感性基因型(OR=2.44,95%CI:1.65-3.61,P<0.00001;OR=1.57,95%CI:1.08-2.28,P=0.02);HLA-DRB1*13和HLA-DRB1*15可能是我国人群慢性乙型肝炎的保护性基因型(OR=0.40,95%CI:0.21-0.79,P=0.008;OR=0.64,95%CI:0.46-0.90,P=0.01).结论:中国人群慢性乙型肝炎的发生与HLADRB1基因的多态性有关,与其他国家人群既有相同点,也有其自身特点.  相似文献   

18.

Background

Atrophic gastritis (AG) is often considered an autoimmune disorder and is associated with other autoimmune diseases. HLA-DRB1 alleles are often associated with autoimmune diseases, however HLA-DRB1 genotyping data in AG patients are lacking. The objective of the study was to evaluate the prevalence of HLA-DRB1 in AG patients.

Methods

The occurrence of HLA-DRB1 alleles was assessed in 89 Italian AG patients (69.1% female) and 313 controls (47.3% females). Genomic DNA was extracted from peripheral venous blood, PCR-coamplified for HLA-DRB1 and typed using a reverse line-blot assay.

Results

Compared to controls, prevalence of HLA-DRB1*03 (28.1% vs. 15.9%, p = 0.01) and HLA-DRB1*04 (25.8% vs. 14.4%, p = 0.01) was greater in AG patients, conferring an OR of 2.05 and 2.07, respectively. HLA-DRB1*01 occurred more frequently in controls than in AG patients (11.5% vs. 3.4%, p = 0.01) conferring an OR of 0.27. AG patients carrying the HLA-DRB1*03 or *04 alleles were characterised by having more frequently autoimmune thyroid disease (70.4% vs. 42.2%, p = 0.01) and intestinal metaplasia (86.4% vs. 62.2%, p = 0.01).

Conclusions

In our population, over 50% of AG patients carry the HLA-DRB1*03 or *04 alleles associated with autoimmune diseases, suggesting that this subset of AG patients has a genetic predisposition to autoimmunity.  相似文献   

19.
Han L  Jia ZT  Li CG 《中华内科杂志》2010,49(11):925-929
目的 研究人尿酸盐转运子1(hURAT1)基因多态性与原发性高尿酸血症的相关性.方法 选择原发性高尿酸血症患者(病例组)215例,正常对照组323例.采用PCR方法分别扩增hURAT1基因第2、3、4外显子及外显子内含子交界处,分析该区域内多态性位点与原发性高尿酸血症的相关性.结果 在中国汉族人群hURAT1基因中,共发现5个多态性位点.其中,在第3内含子区发现1个新的多态性位点11 G>A.病例组AA+AG基因型频率明显高于对照组(11.6%比3.7%,P=3.81×10-4);突变型等位基因(A等位基因)频率明显高于对照组(6.0%比1.9%,P=2.66×10-5).A等位基因构成的基因型AA+AG基因型使高尿酸血症发病风险增加了3.41倍(OR=3.41,95% CI=1.67~6.95).单倍型分析显示,包含第3内含子11 G>A突变型A等位基因的单倍型在病例组中的频率显著高于对照组,与原发性高尿酸血症发病危险性密切相关(69.44%比30.56%,P<0.001).结论 hURAT1基因第3内含子11 G>A多态性与中国汉族人群原发性高尿酸血症密切相关.  相似文献   

20.
Hashimoto's thyroiditis (HT) is an autoimmune disease of the thyroid gland, and like many other autoimmune diseases, it is associated with the HLA and CTLA-4 gene. We have examined the distribution of the HLA DRB4*0101 allele and a CTLA-4 exon 1 A/G polymorphism in Japanese HT patients and controls and investigated possible interactions of these genes with thyroid function. Seventy Japanese HT patients and 105 controls were included in this study. HT was diagnosed on the basis of positivity for thyroid peroxidase (TPO) autoantibodies and the presence of a palpable diffuse goiter. Genotyping was performed by polymerase chain reaction (PCR)-based methods. CTLA-4-GG or -AG was more prevalent in the patients, and the odds ratio for the G allele was 4.95. The frequency of DRB4*0101-positive individuals was significantly higher in HT (odds ratio=2.17). The TSH values of HT patients at the time of diagnosis were compared to CTLA-4 genotype and HLA-DRB4*0101 positivity. They were slightly higher in the CTLA-4-AG group than in the -GG group and significantly higher in the HLA-DRB4*0101-positive group than in the -negative group (p<0.01). When the TSH values were compared in 4 groups based on positivity or negativity for HLA-DRB4*0101 and CTLA-4 GG or AG, they were found to be significantly higher in the CTLA-4-AG and HLA-DRB4*0101-positive group than in the 3 other groups (F=5.75, 3 degrees of freedom, p<0.01). These findings suggest that the interaction between the HLA-DRB4 and CTLA-4 genes determines the thyroid function of TPO-positive goitrous Japanese HT patients.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号